Alothman, Sahar J.
Kang, Keunsoo
Liu, Xuefeng
Krawczyk, Ewa
Azhar, Redha I.
Hu, Rong
Goerlitz, David
Kallakury, Bhaskar V.
Furth, Priscilla A.
Funding for this research was provided by:
King Abdullah Scholarship Program, Ministry Of Higher Education, Kingdom of Saudi Arabia
National Institutes of Health (NCI, NIH RO1CA112176, NCI, NIH P30CA051008, NCI, NIH P30CA051008, NCI, NIH P30CA051008, NCI, NIH RO1CA112176, NCI, NIH RO1CA112176)
Article History
Received: 30 October 2021
Accepted: 1 April 2022
First Online: 22 April 2022
Competing interests
: Financial Competing Interests, Disclosures and Funding: X.L. declares the following competing interests: several patents for conditional reprogramming technology have been awarded to Georgetown University by the United States Patent Office. The license for this technology has been given to a Maryland-based start-up company for commercialization. The inventor, X.L., and Georgetown University receive potential royalties and payments from the company. Several organizations and companies (Propagenix, ATCC, STEMCELL Technologies, etc.) are selling CR cells, media and related reagents. Funding: NCI, NIH RO1CA112176 (P.A.F., B.V.K.), NCI, NIH P30CA051008 (P.A.F., X.L., E.K., R.H., D.G.), King Abdullah Scholarship Program, Ministry of Higher Education, Kingdom of Saudi Arabia (S.J.A.). K.K. & R.I.A. declare no competing financial interests. Non-financial competing interests: S.J.A., K.K. X.L., E.K., R.I.A., R.H., D.G., B.V.K. & P.A.F. declare no non-financial competing interests.